Lesson plan
XC-130
XC-130, or XC130, also known as XC130-A10H, is a dopamine receptor agonist which is under development for the treatment of Parkinson's disease. It is taken orally. The drug is a dopamine D 2 receptor partial agonist, a dopamine D 3 receptor antagonist, an α 1A -adrenergic receptor antagonist, and a serotonin 5-HT 1B , 5-HT 2A , and 5-HT 2B receptor antagonist. Its potency as a dopamine D 2 receptor agonist is similar to that of lisuride. XC-130 produces antiparkinsonian-like effects in animals. Due to its pharmacological profile, the drug is expected to avoid adverse effects and toxicity such as obsessive–compulsive symptoms (related to D 3 agonism), vasoconstriction (related to α 1A -adrenergic and 5-HT 1B agonism), hallucinogenic effects (related to 5-HT 2A agonism), and cardiac valvulopathy (related to 5-HT 2B agonism). It has a notably longer elimination half-life than the relatively short-acting lisuride. The drug is intended to provide similar therapy as existing ergoline dopamine receptor agonists like pergolide and lisuride but with an improved drug profile. XC-130 is under development by Xoc Pharmaceuticals. As of November 2022, it is in phase 1/2 clinical trials. The chemical structure of XC-130 does not yet appear to have been disclosed.
Article summary
XC-130, or XC130, also known as XC130-A10H, is a dopamine receptor agonist which is under development for the treatment of Parkinson's disease. It is taken orally. The drug is a dopamine D 2 receptor partial agonist, a dopamine D 3 receptor antagonist, an α 1A -adrenergic receptor antagonist, and a serotonin 5-HT 1B , 5-HT 2A , and 5-HT 2B receptor antagonist. Its potency as a dopamine D 2 receptor agonist is similar to that of lisuride. XC-130 produces antiparkinsonian-like effects in animals. Due to its pharmacological profile, the drug is expected to avoid adverse effects and toxicity such as obsessive–compulsive symptoms (related to D 3 agonism), vasoconstriction (related to α 1A -adrenergic and 5-HT 1B agonism), hallucinogenic effects (related to 5-HT 2A agonism), and cardiac valvulopathy (related to 5-HT 2B agonism). It has a notably longer elimination half-life than the relatively short-acting lisuride. The drug is intended to provide similar therapy as existing ergoline dopamine receptor agonists like pergolide and lisuride but with an improved drug profile. XC-130 is under development by Xoc Pharmaceuticals. As of November 2022, it is in phase 1/2 clinical trials. The chemical structure of XC-130 does not yet appear to have been disclosed.
Key claims
No claims recorded.
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
No sources recorded.
Key claims and bibliography are generated from the same tracked claims and sources as the article page.